JP2008150314A - Bleaching agent - Google Patents
Bleaching agent Download PDFInfo
- Publication number
- JP2008150314A JP2008150314A JP2006339530A JP2006339530A JP2008150314A JP 2008150314 A JP2008150314 A JP 2008150314A JP 2006339530 A JP2006339530 A JP 2006339530A JP 2006339530 A JP2006339530 A JP 2006339530A JP 2008150314 A JP2008150314 A JP 2008150314A
- Authority
- JP
- Japan
- Prior art keywords
- plant
- extract
- whitening
- phase
- compositae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007844 bleaching agent Substances 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 38
- 241000196324 Embryophyta Species 0.000 claims abstract description 31
- 241000208838 Asteraceae Species 0.000 claims abstract description 15
- 241000010789 Callistemon lanceolatus Species 0.000 claims abstract description 14
- 241000234653 Cyperus Species 0.000 claims abstract description 14
- 244000169656 Isodon coetsa Species 0.000 claims abstract description 14
- 241001415777 Physalis divaricata Species 0.000 claims abstract description 14
- 241000505510 Artemisia roxburghiana Species 0.000 claims abstract description 12
- 241001146180 Jacobaea analoga Species 0.000 claims abstract description 12
- 241000325843 Leontopodium jacotianum Species 0.000 claims abstract description 12
- 241001530209 Swertia Species 0.000 claims abstract description 12
- 241001071804 Gentianaceae Species 0.000 claims abstract description 5
- 241000207923 Lamiaceae Species 0.000 claims abstract description 5
- 241000208292 Solanaceae Species 0.000 claims abstract description 5
- 241000219926 Myrtaceae Species 0.000 claims abstract description 4
- 239000012071 phase Substances 0.000 claims description 51
- 230000002087 whitening effect Effects 0.000 claims description 40
- 239000008346 aqueous phase Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 241000234646 Cyperaceae Species 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- -1 methanol and ethanol Chemical class 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000469 ethanolic extract Substances 0.000 description 14
- 239000002304 perfume Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 238000005342 ion exchange Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 12
- 239000000419 plant extract Substances 0.000 description 12
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000008099 melanin synthesis Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 9
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 9
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 239000000401 methanolic extract Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004945 emulsification Methods 0.000 description 7
- 229940057995 liquid paraffin Drugs 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 229940032094 squalane Drugs 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- 235000011118 potassium hydroxide Nutrition 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 229910021538 borax Inorganic materials 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 229940055577 oleyl alcohol Drugs 0.000 description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 4
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000004328 sodium tetraborate Substances 0.000 description 4
- 235000010339 sodium tetraborate Nutrition 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 241001106044 Physalis Species 0.000 description 3
- 206010064127 Solar lentigo Diseases 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CCWPSKZBVMNDLT-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-phenylmethanone;sodium Chemical compound [Na].OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 CCWPSKZBVMNDLT-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000378544 Melaleuca quinquenervia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000093225 Physalis minima Species 0.000 description 1
- 235000009230 Physalis pubescens Nutrition 0.000 description 1
- 235000002491 Physalis viscosa Nutrition 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000128206 Pyracantha coccinea Species 0.000 description 1
- 235000003105 Pyracantha coccinea Nutrition 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000967896 Senecio laetus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- FCEVNJIUIMLVML-UHFFFAOYSA-N spartioidine Natural products O1C(=O)C(=CC)CC(=C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 FCEVNJIUIMLVML-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は特定の植物抽出物を含む美白剤に関する。 The present invention relates to a whitening agent containing a specific plant extract.
皮膚のしみ・そばかすなどの色素沈着は、ホルモンの異常や紫外線、皮膚局所の炎症が原因となってメラニンが過剰に形成され、これが皮膚内に沈着するものと考えられている。皮膚の色素沈着の原因となるこのメラニンは、表皮基底層にある色素細胞(メラノサイト)内のメラノソームと呼ばれる小器官において生成され、生成したメラニンは周囲角化細胞(ケラチノサイト)に取り込まれる。このメラノサイト内におけるメラニンは、チロシンが酵素チロシナーゼの作用によりドーパキノンを経て酵素的または非酵素的な酸化反応により黒色のメラニンへと変化して生成される。したがって、第一段階の反応であるチロシナーゼの活性を抑制することが、メラニンの生成を抑制するうえで重要である。
上記のような色素異常の予防・改善を目的として美白作用を有する物質、すなわち、メラニン生成を抑制する物質が主に用いられており、例えば、ビタミンCを大量に経口投与する方法、グルタチオン等を注射する方法、あるいは、コウジ酸、ビタミンC及びその誘導体、システイン等を軟膏、クリーム、ローション等の形態で局所に塗布する方法などが知られている。
しかしながら、チロシナーゼの活性を抑制する化合物はハイドロキノンを除いてはその効果の発現がきわめて緩慢であるため、皮膚色素沈着の改善効果が十分でない。一方、ハイドロキノンは効果が認められるが、感作性があるため一般の使用が制限されている。そこでその安全性を向上させるため、高級脂肪酸のモノエステルやアルキルモノエーテルなどにする試み(特許文献1参照)がなされている。
しかしながら、このような高級脂肪酸のモノエステル類は体内の加水分解酵素によって分解されるため必ずしも安全であるとはいい難く、またエーテル類も安全性の面で充分に満足するものが得られていない。
It is thought that pigmentation such as skin spots and freckles causes excessive melanin formation due to hormonal abnormalities, ultraviolet rays, and local inflammation of the skin, which deposits in the skin. This melanin, which causes skin pigmentation, is produced in organelles called melanosomes in pigment cells (melanocytes) in the basal layer of the epidermis, and the produced melanin is taken up by surrounding keratinocytes (keratinocytes). Melanin in the melanocytes is produced by converting tyrosine into black melanin through an enzymatic or non-enzymatic oxidation reaction via dopaquinone by the action of the enzyme tyrosinase. Therefore, it is important to suppress the activity of tyrosinase, which is the first stage reaction, in order to suppress the production of melanin.
Substances having a whitening effect for the purpose of preventing or improving pigment abnormalities as described above, that is, substances that suppress melanin production are mainly used. For example, a method of orally administering vitamin C in large amounts, glutathione, etc. A method of injection or a method of locally applying kojic acid, vitamin C and its derivatives, cysteine, etc. in the form of an ointment, cream, lotion or the like is known.
However, the compounds that suppress the activity of tyrosinase exhibit very slow effects except for hydroquinone, and thus the effect of improving skin pigmentation is not sufficient. On the other hand, hydroquinone has an effect, but its general use is limited because of its sensitization. In order to improve the safety, attempts have been made to use higher fatty acid monoesters and alkyl monoethers (see Patent Document 1).
However, such monoesters of higher fatty acids are not necessarily safe because they are degraded by hydrolyzing enzymes in the body, and ethers are not sufficiently satisfactory in terms of safety. .
そこで、本発明者らは種々の植物抽出物についてメラニン生成抑制効果を調べた結果、これまでにかかる効果を有することが知られていなかった特定の植物抽出物が優れたメラニン生成抑制作用を有していることを見い出し、本発明を完成するに至った。 Therefore, as a result of examining the melanin production inhibitory effect of various plant extracts, the present inventors have found that a specific plant extract that has not been known to have such an effect has an excellent melanin production inhibitory action. As a result, the present invention has been completed.
本発明は、ナス科(Solanaceae)植物のフィサリス ディバリカタ( Physalis divaricata)(同義語 Physalis minima 、和名 ネパールホオズキ、英名 ground cherry、ネパール現地名 isamgoli, jangali mewa, patpate, golbhede jhar)、キク科(Compositae)植物のセネシオ クリサンセモイデス( Senecio chrysanthemoides )(同義語 Senecio laetus 、ネパール現地名 bijauri phul)、シソ科(Labiatae)植物のラブドシア コエッツァ( Rabdosia coetsa )(ネパール現地名 Thamo sing, jwahane, mirre, chyandre, surchendro)、カヤツリグサ科(Cyperaceae)植物のシペルス エスピー.( Cyperus sp.)(ネパール現地名 Namiramjan)、キク科(Compositae)植物のレオントポディウム ヤコティアヌム( Leontopodium jacotianum )(ネパール現地名 Taa)、リンドウ科(Gentianaceae)植物のスウェルティア アラタ( Swertia alata )(ネパール現地名 Tikta)、キク科(Compositae)植物のアルテミシア ロクスブルギアナ( Artemisia roxburghiana )(ネパール現地名 Patse)、フトモモ科(Myrtaceae)植物のカリステモン ランセオラタス( Callistemon lanceolatus )からなる群より選択される1種又は2種以上の植物の抽出物を含むことを特徴とする美白剤である。 The present invention relates to the physalis divaricata (Solanaceae) plant (synonyms Physalis minima, Japanese name Nepalese physalis, English name ground cherry, Nepal local name isamgoli, jangali mewa, patpate, golbhede jhar), Compositae ) The plant Senecio chrysanthemoides (synonymous Senecio laetus, Nepal local name bijauri phul), Labiatae plant Rabdosia coetsa (Nepal local name Thamo sing, jwahane, mirre, mirre, mirre, mirre , surchendro), Cyperaceae plant Cyperus sp. (Cyperus sp.) (Nepal local name: Namiramjan), Compositae plant, Leontopodium jacotianum (Nepal local name: Taa), Gentianaceae plant, Sertia alata (Swertia alata) (Nepal) One selected from the group consisting of the local name Tikta), Artemisia roxburghiana (Compositae) plant, Artemisia roxburghiana (Nepal local name Patse), and the callistemon lanceolatus (Callistemon lanceolatus). A whitening agent comprising an extract of two or more kinds of plants.
本発明は、上記の美白剤を用いて肌の美白を行うことを特徴とする美白方法である。 The present invention is a whitening method characterized in that skin whitening is performed using the above-described whitening agent.
本発明は、上記の美白剤を水相または油相に添加して美白用皮膚外用剤を製造することを特徴とする美白用皮膚外用剤の製造方法である。 The present invention is a method for producing a whitening skin external preparation, wherein the above-described whitening agent is added to an aqueous phase or an oil phase to produce a whitening skin external preparation.
本発明の美白剤は、優れたメラニン生成抑制作用を有しており、日焼け後の色素沈着・しみ・そばかす・肝斑等の淡色化、美白に優れた効果を有するものである。 The whitening agent of the present invention has an excellent inhibitory action on melanin production, and has excellent effects on lightening and whitening of pigmentation, stains, freckles, and liver spots after sunburn.
また本発明によれば、日焼け後の色素沈着・しみ・そばかす・肝斑等の淡色化、美白に優れた効果を有すると共に、安全性にも優れた美白方法が提供される。 Further, according to the present invention, there is provided a whitening method having effects excellent in lightening and whitening of pigmentation / stain / freckle / liver spots after sunburn, and also in safety.
さらに、本発明による美白用皮膚外用剤の製造方法によれば、メラニン生成抑制作用を有しており、日焼け後の色素沈着・しみ・そばかす・肝斑等の淡色化、美白に優れた効果を有すると共に、安全性にも優れた美白用皮膚外用剤を製造することができる。 Furthermore, according to the method for producing a skin whitening preparation for skin whitening according to the present invention, it has a melanin production inhibitory effect, and has excellent effects on lightening whitening, such as pigmentation, stains, freckles, and liver spots after sunburn. It is possible to produce a skin whitening preparation for skin whitening that is excellent in safety.
以下に、本発明の最良の実施の形態について説明する。
本発明の美白剤に用いられるナス科(Solanaceae)植物の Physalis divaricata 、キク科(Compositae)植物の Senecio chrysanthemoides 、シソ科(Labiatae)植物の Rabdosia coetsa 、カヤツリグサ科(Cyperaceae)植物の Cyperus sp.(ネパール現地名 Namiramjan)、キク科(Compositae)植物の Leontopodium jacotianum 、リンドウ科(Gentianaceae)植物の Swertia alata 、キク科(Compositae)植物の Artemisia roxburghiana 、フトモモ科(Myrtaceae)植物の Callistemon lanceolatus について、以下に詳述する。これらの植物は、いずれもネパールに生える植物である。
なお本発明の美白剤は、好ましくは実質的に上記植物抽出物のみからなるものであるが、その他の成分を含んでいても良い。
The best mode of the present invention will be described below.
Physalis divaricata of Solanaceae plant, Senecio chrysanthemoides of Compositae plant, Rabdosia coetsa of Labiatae plant, Cyperus sp. Of Cyperaceae plant used for whitening agent of the present invention The local name Namiramjan), Leontopodium jacotianum of the Compositae plant, Swertia alata of the Gentianaceae plant, Artemisia roxburghiana of the Compositae plant, and Callistemon lanceolatus of the Myrtaceae plant are detailed below. To do. These plants are all plants that grow in Nepal.
The whitening agent of the present invention preferably consists essentially of the above plant extract, but may contain other components.
ナス科(Solanaceae)植物の Physalis divaricata は、ホオズキ属植物であり、中国名を黄姑娘という。中国では全草または果実(天泡子)を、駆虫、黄疸、利尿、喘息に用いる。またその全草は、骨折、できもの、潰瘍などに用いられる。
キク科(Compositae)植物の Senecio chrysanthemoides は、キオン(セネキオ)属植物であり、中国名を菊葉千里光という。高さ60〜180cmになる大型の多年草で、ヒマラヤ(パキスタンからアッサム)山地、ネパール南部、中国南西部に分布し、アルカロイド(セネキオフィリン:seneciophylline)を含有して家畜には有毒であるが、ネパールでは薬用にする。
シソ科(Labiatae)植物の Rabdosia coetsa は、ヤマハッカ属植物であり、最近ではイソドン Isodon 属に分類される双子葉植物である。眼病に用いられる。
カヤツリグサ科(Cyperaceae)植物の Cyperus sp.(ネパール現地名 Namiramjan)は、カヤツリグサ属植物であり、単子葉植物である。
Physalis divaricata, a solanaceae plant, is a physalis plant, and its Chinese name is Huang Xiao daughter. In China, the whole plant or fruit (Temago) is used for anthelmintic, jaundice, diuresis and asthma. The whole plant is used for fractures, artifacts, ulcers and the like.
Senecio chrysanthemoides, a compositae plant, is a genus of the genus Sioncio and its Chinese name is called Chisato Kikuba. A large perennial plant with a height of 60-180 cm, distributed in the Himalayas (Pakistan to Assam) Mountains, southern Nepal, and southwestern China. It contains alkaloids (seneciophylline) and is toxic to livestock. Then it is medicinal.
Rabdosia coetsa, a Labiatae plant, is a dicotyledonous plant that is recently classified into the genus Isodon. Used for eye diseases.
Cyperus sp. (Nepalese local name Namiramjan), a family of Cyperaceae, is a genus of genus Cyperaceae and is a monocotyledonous plant.
キク科(Compositae)植物の Leontopodium jacotianum は、ウスユキソウ属植物であり、カシミール〜ブータン、ネパール南・南東部の高山帯に分布し、風にさらされた草地や礫地に生育する。茎、葉ともに白い綿毛でおおわれた様子を薄雪にたとえて、属名はつけられた。花序の基部に数枚から十数枚の苞葉が発達し、それらの苞葉は白綿毛によって密におおわれているうえに、放射状に並んでいるために、全体として花のように見える。
リンドウ科(Gentianaceae)植物の Swertia alata は、センブリ属植物であり、双子葉植物の多年草である。
キク科(Compositae)植物の Artemisia roxburghiana は、ヨモギ属植物であり、双子葉植物である。葉は互生し、細かく切れ込み、花は風媒花であり、頭花は小さく、下向きに咲き、花粉の刺が円く、低い。
The Compositae plant, Leontopodium jacotianum, is a plant belonging to the genus Pleurotus, distributed in the alpine belts of Kashmir to Bhutan, south and southeast of Nepal, and grows in grassy and gravel areas exposed to wind. The genus name was given, as if the stem and leaves were covered with white fluff. Several to ten or more buds are developed at the base of the inflorescence, and these buds are covered with white fluff and are arranged in a radial pattern, so they look like flowers as a whole.
The Gentianaceae plant Swertia alata is a genus plant and a dicotyledonous perennial plant.
The Compositae plant Artemisia roxburghiana is a Artemisia plant and a dicotyledonous plant. Leaves are alternating, finely cut, flowers are airborne flowers, head flowers are small, bloom downwards, pollen bites are round and low.
フトモモ科(Myrtaceae)植物の Callistemon lanceolatus は、和名をハナマキ、キンポウジュといい、オーストラリア大陸及びタスマニア島に十数種分布している寒さにやや弱い常緑の低木または高木で、花弁が退化して、梅の花の芯のような、雄しべだけが発達し、花序が瓶や試験管を洗うためのブラシにように見えることから、英語では瓶ブラシの木として知られている。樹高は2mから10mくらいで、葉は被針形で枝に密に付いている。葉には精油を含み、香りのよいものもある。花は初夏に咲き、花序は円柱状で、長さ5〜10cmくらいである。雄しべが密について美しいものと、比較的まばらなものがある。花色は赤か黄色だが、赤紫を帯びたものや、観賞用の花としては珍しい黄緑色のものもある。 Callistemon lanceolatus, a myrtaceae plant, is called Hanamaki, Buttercup, and is an evergreen shrub or tree that is slightly weak in cold weather and distributed on the Australian continent and Tasmania Island. It is known as the bottle brush tree in English because only the stamens, like the plum blossom core, have developed and the inflorescences look like brushes for washing bottles and test tubes. The tree height is about 2 to 10 m, and the leaves are needle-shaped and closely attached to the branches. The leaves contain essential oils and some are fragrant. The flowers bloom in early summer and the inflorescences are cylindrical and are about 5-10 cm long. There are beautiful stamens and relatively sparse ones. The flower color is red or yellow, but some are reddish-purple and some are yellow-green, which is rare for ornamental flowers.
本発明に用いられる植物抽出物は、上記植物の葉、地下茎を含む茎、根、果実、植物全草等を抽出溶媒と共に浸漬または加熱還流した後、濾過し、濃縮して得られる。本発明に用いられる抽出溶媒は、通常抽出に用いられる溶媒であれば何でもよく、特にメタノール、エタノール等のアルコール類、含水アルコール類、アセトン、酢酸エチルエステル等の有機溶媒を単独あるいは組み合わせて用いることができる。本発明の美白剤は好ましくは上記植物抽出物からなるものであり、上記植物を単独で用いた植物抽出物であっても、あるいは混合して用いた植物抽出物であっても良い。 The plant extract used in the present invention is obtained by immersing or heating and refluxing the above-mentioned plant leaves, stems including root stems, roots, fruits, whole plant plants and the like together with an extraction solvent, followed by filtration and concentration. The extraction solvent used in the present invention is not particularly limited as long as it is usually used for extraction, and in particular, organic solvents such as alcohols such as methanol and ethanol, hydrous alcohols, acetone and ethyl acetate are used alone or in combination. Can do. The whitening agent of the present invention preferably comprises the above plant extract, and may be a plant extract using the above plant alone or a plant extract using a mixture.
本発明に用いられる Physalis divaricata は、地上部を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Senecio chrysanthemoides は、全草を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Rabdosia coetsa は、地上部を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Cyperus sp.(ネパール現地名 Namiramjan)は、全草を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Leontopodium jacotianum は、全草を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Swertia alata は、地上部を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Artemisia roxburghiana は、全草を用いるのが好ましいが、他の部位を用いることもできる。
本発明に用いられる Callistemon lanceolatus は、地上部を用いるのが好ましいが、他の部位を用いることもできる。
The physalis divaricata used in the present invention preferably uses the above-ground part, but other parts can also be used.
Senecio chrysanthemoides used in the present invention is preferably whole plant, but other sites can also be used.
Rabdosia coetsa used in the present invention preferably uses the above-ground part, but other parts can also be used.
Cyperus sp. (Nepal local name: Namiramjan) used in the present invention is preferably whole plant, but other parts can also be used.
Leontopodium jacotianum used in the present invention preferably uses whole grass, but other parts can also be used.
Swertia alata used in the present invention preferably uses the above-ground part, but other parts can also be used.
Artemisia roxburghiana used in the present invention is preferably whole plant, but other sites can be used.
The Callistemon lanceolatus used in the present invention preferably uses the above-ground part, but other parts can also be used.
本発明においては、自生あるいは栽培何れで得られたものでも使用でき、また、上記植物抽出物は2種以上を混合して用いてもよい。 In this invention, what was obtained by either self-growth or cultivation can be used, and the said plant extract may mix and use 2 or more types.
このようにして得られた上記植物またはその抽出物は、いずれも優れたメラニン生成抑制効果を有する。このような植物またはその抽出物は、水相または油相に添加することにより、優れた美白効果を奏する美白用皮膚外用剤を製造することができる。 Any of the above-mentioned plants or extracts thereof thus obtained has an excellent melanin production inhibitory effect. By adding such a plant or an extract thereof to an aqueous phase or an oil phase, it is possible to produce a skin whitening external preparation that exhibits an excellent whitening effect.
上記植物またはその抽出物を皮膚外用剤に配合して用いる場合、外用剤全量中に乾燥重量として0.0005〜20質量%配合するのが好ましく、より好ましくは0.001〜10質量%である。0.0005質量%未満では本発明のメラニン生成抑制効果が十分に発揮され難く、一方、20質量%を超えると製剤化が難しいので好ましくない。また、10質量%を超えて配合してもさほど大きな効果の向上は認められない。 When the above-mentioned plant or extract thereof is blended and used in a skin external preparation, it is preferably blended in the total amount of the external preparation in a dry weight of 0.0005 to 20% by mass, more preferably 0.001 to 10% by mass. . If it is less than 0.0005% by mass, the melanin production inhibitory effect of the present invention is not sufficiently exerted. Moreover, even if it mixes exceeding 10 mass%, the improvement of the big effect is not recognized.
上記の皮膚外用剤には、上記必須成分以外に、通常化粧品や医薬品等の皮膚外用剤に用いられる成分、例えば、その他の美白剤、保湿剤、酸化防止剤、油性成分、紫外線吸収剤、界面活性剤、増粘剤、アルコール類、粉末成分、色材、水性成分、水、各種皮膚栄養剤等を必要に応じて適宜配合することができる。 In addition to the above essential components, the above-mentioned skin external preparations are usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, other whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, interfaces. Activators, thickeners, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.
その他、エデト酸二ナトリウム、エデト酸三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸等の金属封鎖剤、カフェイン、タンニン、ベラパミル、トラネキサム酸およびその誘導体、甘草抽出物、グラブリジン、火棘の果実の熱水抽出物、各種生薬、酢酸トコフェロール、グリチルリチン酸およびその誘導体またはその塩等の薬剤、ビタミンC、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド、アルブチン、コウジ酸、ルシノール、エラグ酸、カモミラ等の他の美白剤、グルコース、フルクトース、マンノース、ショ糖、トレハロース等の糖類なども適宜配合することができる。 Others, disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extract, grabrizine , Hot water extract of fire thorn fruit, various herbal medicines, drugs such as tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, glucoside ascorbate, arbutin, kojic acid, lucinol, ellag Other whitening agents such as acid and chamomile, and sugars such as glucose, fructose, mannose, sucrose, and trehalose can be appropriately blended.
本発明の美白剤を配合した皮膚外用剤とは、通常医薬品、医薬部外品、化粧品等の分野で用いられるものを指し、その剤型は本発明の効果が発揮される限り、特に限定されるものではない。例えば、軟膏、クリーム、乳液、ローション、パック、浴用剤等、従来皮膚外用剤に用いられるものであればいずれでもよい。 The topical skin preparation containing the whitening agent of the present invention refers to those usually used in the fields of pharmaceuticals, quasi drugs, cosmetics, etc., and the dosage form is particularly limited as long as the effect of the present invention is exhibited. It is not something. For example, any ointment, cream, milky lotion, lotion, pack, bath preparation and the like conventionally used for external preparations for skin may be used.
次に実施例を挙げ、本発明をさらに詳細に説明する。ここで、配合量は質量%である。
実施例に先立ち、本発明の植物抽出物のメラニン生成抑制効果および美白効果に関する試験方法とその結果について説明する。
EXAMPLES Next, an Example is given and this invention is demonstrated further in detail. Here, a compounding quantity is the mass%.
Prior to the examples, the test method and the results regarding the melanin production inhibitory effect and the whitening effect of the plant extract of the present invention will be described.
(試験方法およびその結果)
1.試料の調製
以下に、本実施例で用いた植物抽出物の調製法について述べるが、これらの植物原料はいずれもネパール産の植物を用いた。
(1)Physalis divaricata 抽出液
Physalis divaricata の地上部0.629gを、室温で1週間メタノール20mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.078gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(Test method and results)
1. Preparation of sample Hereinafter, the preparation method of the plant extract used in this example will be described, and all of these plant materials used Nepalese plants.
(1) Physalis divaricata extract
0.629 g of the above-ground part of Physalis divaricata was immersed in 20 mL of methanol for 1 week at room temperature, the extract was filtered and the solvent was distilled off to obtain 0.078 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(2)Senecio chrysanthemoides 抽出液
Senecio chrysanthemoides の全草4.194gを、室温で1週間メタノール30mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.583gを得た。抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(2) Senecio chrysanthemoides extract
4.194 g of whole plant of Senecio chrysanthemoides was immersed in 30 mL of methanol at room temperature for 1 week, the extract was filtered and the solvent was distilled off to obtain 0.583 g of methanol extract. The extract was dissolved in 1% by mass in DMSO, the solution was diluted to adjust the concentration, and the following experiment was performed using this.
(3)Rabdosia coetsa 抽出液
Rabdosia coetsa の地上部20.0gを、室温で1週間メタノール200mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物1.136gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(3) Rabdosia coetsa extract
20.0 g of the above-ground part of Rabdosia coetsa was immersed in 200 mL of methanol at room temperature for 1 week, the extract was filtered and the solvent was distilled off to obtain 1.136 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(4)Cyperus sp.(ネパール現地名 Namiramjan)抽出液
Cyperus sp.(ネパール現地名 Namiramjan)の全草1.289gを、室温で1週間メタノール20mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.068gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(4) Cyperus sp. (Nepal local name: Namiramjan) extract
1.289 g of whole plant of Cyperus sp. (Nepal local name Namiramjan) was immersed in 20 mL of methanol for 1 week at room temperature, the extract was filtered and the solvent was distilled off to obtain 0.068 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(5)Leontopodium jacotianum 抽出液
Leontopodium jacotianum の全草0.735gを、室温で1週間メタノール20mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.029gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(5) Leontopodium jacotianum extract
0.735 g of whole plant of Leontopodium jacotianum was immersed in 20 mL of methanol at room temperature for 1 week, the extract was filtered and the solvent was distilled off to obtain 0.029 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(6)Swertia alata 抽出液
Swertia alata の地上部0.330gを、室温で1週間メタノール20mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.063gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(6) Swertia alata extract
0.330 g of the above-ground part of Swertia alata was immersed in 20 mL of methanol for 1 week at room temperature, the extract was filtered and the solvent was distilled off to obtain 0.063 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(7)Artemisia roxburghiana 抽出液
Artemisia roxburghiana の全草3.970gを、室温で1週間メタノール50mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.325gを得た。この抽出物をDMSOに1質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(7) Artemisia roxburghiana extract
3.970 g of whole plant of Artemisia roxburghiana was immersed in 50 mL of methanol for 1 week at room temperature, the extract was filtered and the solvent was distilled off to obtain 0.325 g of methanol extract. This extract was dissolved in 1% by mass in DMSO, and this solution was diluted to adjust the concentration. Using this, the following experiment was conducted.
(8)Callistemon lanceolatus 抽出液
Callistemon lanceolatus の地上部2.53gを、室温で1週間メタノール20mLに浸漬し、抽出液をろ過、溶媒を留去し、メタノール抽出物0.23gを得た。抽出物をDMSOに2質量%溶かし、この溶液を希釈して濃度を調整し、これを用いて以下の実験を行った。
(8) Callistemon lanceolatus extract
2.53 g of the above-ground part of Callistemon lanceolatus was immersed in 20 mL of methanol for 1 week at room temperature, the extract was filtered and the solvent was distilled off to obtain 0.23 g of methanol extract. The extract was dissolved in 2% by mass in DMSO, this solution was diluted to adjust the concentration, and the following experiment was performed using this.
2.細胞培養法
マウスB16メラノーマ細胞を使用した。イーグルMEMにFBS(10%)とαMSH(10ng/mL)を含む培地を試験培地とした。細胞は75cm2フラスコにFBS(10%)を含むイーグルMEM培地を用いてCO2インキュベーター内で培養し、増殖させた。細胞をトリプシン溶液で剥がし、FBS(10%)を含むイーグルMEM培地を加え、1,100rpmで遠心して細胞を集めた。ディシュ(100x20mm)に細胞を300,000になるように播種し、5mLのFBS(10%)を含むイーグルMEM培地で1日間培養後、試験試料を各濃度含む試験培地で3日間培養を続け、以下の方法で細胞あたりのメラニン量の測定を行った。
2. Cell culture method Mouse B16 melanoma cells were used. A medium containing Eagle's MEM containing FBS (10%) and αMSH (10 ng / mL) was used as a test medium. The cells were grown in a CO 2 incubator using Eagle's MEM medium containing FBS (10%) in a 75 cm 2 flask. The cells were detached with a trypsin solution, Eagle MEM medium containing FBS (10%) was added, and the cells were collected by centrifugation at 1,100 rpm. Cells were seeded at 300,000 in a dish (100 × 20 mm), cultured for 1 day in Eagle's MEM medium containing 5 mL of FBS (10%), and then cultured for 3 days in the test medium containing each concentration of the test sample. The amount of melanin per cell was measured by the following method.
3.メラニン量の測定
細胞を5mLのトリプシン溶液で剥がし、15mLの遠心チューブに移した。デッシュに5mLのPBSを加え、同じ遠心チューブに移した。細胞数をCoulterZ1で測定した後に、1,100rpmで遠心して細胞を集めた。風乾後、2Mの水酸化ナトリウム溶液を100μL/10,000細胞になるように加え、60℃で3分間暖め、攪拌してメラニンを溶解した。その50μLを水150μLで希釈し、マイクロプレートリーダーで500nmの吸光度を測定した。結果は被験植物エキス無添加群に対する抑制率(%)で求めた。その結果を表1に示した。また、参考例として、すでにメラニン生成抑制作用のあることが知られているアルブチンについても上記と同様の試験を行った。その結果を併せて表1に示した。細胞増殖については、試験したすべての試料において「抑制なし」の結果であった。
3. Measurement of the amount of melanin Cells were detached with 5 mL of trypsin solution and transferred to a 15 mL centrifuge tube. 5 mL of PBS was added to the dish and transferred to the same centrifuge tube. After measuring the cell number with Coulter Z1, the cells were collected by centrifugation at 1,100 rpm. After air drying, 2M sodium hydroxide solution was added to 100 μL / 10,000 cells, warmed at 60 ° C. for 3 minutes, and stirred to dissolve melanin. 50 μL of this was diluted with 150 μL of water, and the absorbance at 500 nm was measured with a microplate reader. The result was calculated | required by the suppression rate (%) with respect to a test plant extract no addition group. The results are shown in Table 1. As a reference example, arbutin, which is already known to have a melanin production inhibitory effect, was also tested in the same manner as described above. The results are also shown in Table 1. Cell proliferation was a “no suppression” result in all samples tested.
表1の結果より、Physalis divaricata 、Senecio chrysanthemoides 、Rabdosia coetsa 、Cyperus sp.(ネパール現地名 Namiramjan)、Leontopodium jacotianum 、Swertia alata 、Artemisia roxburghiana 、 Callistemon lanceolatus の抽出物は、細胞増殖に影響を与えることなくメラニンの生成を抑制することがわかり、アルブチンと同様に優れたメラニン生成抑制作用をもつことがわかった。 From the results in Table 1, the extract of Physalis divaricata, Senecio chrysanthemoides, Rabdosia coetsa, Cyperus sp. (Nepal local name Namiramjan), Leontopodium jacotianum, Swertia alata, Artemisia roxburghiana, Callistemon lanceolatus has no effect on cell proliferation. It was found that it suppresses the production of melanin, and has an excellent inhibitory effect on melanin production like arbutin.
4.美白効果試験
(4−1)美白剤配合皮膚外用剤の調製
美白剤を各試料として、下記の処方に調製した。調製方法は常法に従いアルコール相および水相を調製して行った。
(アルコール相)
99%エタノール 70.0 質量%
「表2」記載の美白剤 「表2」記載の量
(水相)
グリセリン 5.0
イオン交換水 残余
4). Whitening effect test (4-1) Preparation of whitening agent-containing skin external preparation A whitening agent was prepared for each sample as follows. The preparation method was carried out by preparing an alcohol phase and an aqueous phase according to a conventional method.
(Alcohol phase)
99% ethanol 70.0 mass%
Whitening agent described in “Table 2” Amount described in “Table 2” (aqueous phase)
Glycerin 5.0
Ion exchange water
(4−2)試験方法
紫外線を曝露したパネル(n=5)の皮膚を対象として、紫外線を曝露した日の14日後より、各処方液を1日1回ずつ8週間塗布した。塗布終了後、紫外線照射によって誘導される色素沈着に対して抑制効果があるかどうかを試験終了時に4段階の評価基準で調べた。結果を表2に示す。
(評価基準)
4:著効
3:有効
2:やや有効
1:効果なし
(4-2) Test Method For each skin of the panel (n = 5) exposed to ultraviolet rays, each prescription solution was applied once a day for 8 weeks from 14 days after the day of exposure to ultraviolet rays. After the application was completed, whether or not there was an inhibitory effect on the pigmentation induced by ultraviolet irradiation was examined at the end of the test using four evaluation criteria. The results are shown in Table 2.
(Evaluation criteria)
4: Excellent effect 3: Effective 2: Slightly effective 1: No effect
表2より明らかなように、紫外線を曝露したパネルに対する Physalis divaricata 、Senecio chrysanthemoides 、Rabdosia coetsa 、Cyperus sp.(ネパール現地名 Namiramjan)、Leontopodium jacotianum 、Swertia alata 、Artemisia roxburghiana を添加した処方液には美白効果が認められた。 As can be seen from Table 2, whitening effect is applied to the prescription solution containing Physalis divaricata, Senecio chrysanthemoides, Rabdosia coetsa, Cyperus sp. Was recognized.
以下に、本発明の美白剤を配合した皮膚外用剤の実施例を挙げる。配合した美白剤は上記で調製したものを用いた。配合量は質量%を表す。実施例1〜16で得られた皮膚外用剤はいずれも美白効果試験において効果が認められた。 Examples of the external preparation for skin containing the whitening agent of the present invention will be given below. The whitening agent used was the one prepared above. A compounding quantity represents the mass%. The skin external preparations obtained in Examples 1 to 16 were all effective in the whitening effect test.
実施例1 クリーム
(処方)
ステアリン酸 5.0 質量%
ステアリルアルコール 4.0
イソプロピルミリステート 18.0
グリセリンモノステアリン酸エステル 3.0
プロピレングリコール 10.0
Physalis divaricata エタノール抽出物 0.01
苛性カリ 0.2
亜硫酸水素ナトリウム 0.01
防腐剤 適量
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールと Physalis divaricata エタノール抽出物 エタノール抽出物と苛性カリを加え溶解し、加熱して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を徐々に加え、全部加え終わってからしばらくその温度に保ち反応を起こさせる。その後、ホモミキサーで均一に乳化し、よくかきまぜながら30℃まで冷却する。
Example 1 Cream (Prescription)
Stearic acid 5.0% by mass
Stearyl alcohol 4.0
Isopropyl myristate 18.0
Glycerol monostearate 3.0
Propylene glycol 10.0
Physalis divaricata ethanol extract 0.01
Caustic potash 0.2
Sodium bisulfite 0.01
Preservative Appropriate amount Perfume Appropriate amount Ion-exchange water Residue
Propylene glycol and Physalis divaricata ethanol extract are added to ion-exchanged water, dissolved in ethanol extract and caustic potash, and heated to 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase, and after the addition is complete, the temperature is maintained for a while to cause the reaction. Thereafter, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well.
実施例2 クリーム
(処方)
ステアリン酸 2.0 質量%
ステアリルアルコール 7.0
水添ラノリン 2.0
スクワラン 5.0
2−オクチルドデシルアルコール 6.0
ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0
グリセリンモノステアリン酸エステル 2.0
プロピレングリコール 5.0
Senecio chrysanthemoides ヘキサン抽出物 0.05
亜硫酸水素ナトリウム 0.03
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールを加え、加熱して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却する。
Example 2 Cream (Prescription)
Stearic acid 2.0% by mass
Stearyl alcohol 7.0
Hydrogenated Lanolin 2.0
Squalane 5.0
2-Octyldodecyl alcohol 6.0
Polyoxyethylene (25 mol) cetyl alcohol ether 3.0
Glycerin monostearate ester 2.0
Propylene glycol 5.0
Senecio chrysanthemoides hexane extract 0.05
Sodium bisulfite 0.03
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Propylene glycol is added to ion-exchanged water and heated to 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). Preliminarily emulsify by adding an oil phase to the aqueous phase, uniformly emulsify with a homomixer, and then cool to 30 ° C. while stirring well.
実施例3 クリーム
(処方)
固形パラフィン 5.0 質量%
ミツロウ 10.0
ワセリン 15.0
流動パラフィン 41.0
グリセリンモノステアリン酸エステル 2.0
ポリオキシエチレン(20モル)ソルビタンモノラウリン酸エステル 2.0
石けん粉末 0.1
硼砂 0.2
Rabdosia coetsa アセトン抽出物 0.05
亜硫酸水素ナトリウム 0.03
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水に石けん粉末と硼砂を加え、加熱溶解して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相をかきまぜながら徐々に加え反応を行う。反応終了後、ホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却する。
Example 3 Cream (Prescription)
Solid paraffin 5.0% by mass
Beeswax 10.0
Vaseline 15.0
Liquid paraffin 41.0
Glycerin monostearate ester 2.0
Polyoxyethylene (20 mol) sorbitan monolaurate 2.0
Soap powder 0.1
Borax 0.2
Rabdosia coetsa acetone extract 0.05
Sodium bisulfite 0.03
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Add soap powder and borax to ion-exchanged water, dissolve by heating and maintain at 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). The reaction is gradually added while stirring the oil phase in the aqueous phase. After completion of the reaction, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well after emulsification.
実施例4 乳液
(処方)
ステアリン酸 2.5 質量%
セチルアルコール 1.5
ワセリン 5.0
流動パラフィン 10.0
ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0
ポリエチレングリコール1500 3.0
トリエタノールアミン 1.0
カルボキシビニルポリマー 0.05
Cyperus sp.(ネパール現地名 Namiramjan)酢酸エチルエステル抽出物 0.01
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
少量のイオン交換水にカルボキシビニルポリマーを溶解する(A相)。残りのイオン交換水にポリエチレングリコール1500とトリエタノールアミンを加え、加熱溶解して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を加え予備乳化を行い、A相を加えホモミキサーで均一乳化し、乳化後よくかきまぜながら30℃まで冷却する。
Example 4 Latex (Prescription)
Stearic acid 2.5% by mass
Cetyl alcohol 1.5
Vaseline 5.0
Liquid paraffin 10.0
Polyoxyethylene (10 mol) monooleate 2.0
Polyethylene glycol 1500 3.0
Triethanolamine 1.0
Carboxyvinyl polymer 0.05
Cyperus sp. (Nepal local name Namiramjan) Acetic acid ethyl ester extract 0.01
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Dissolve the carboxyvinyl polymer in a small amount of ion-exchanged water (A phase). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating and maintained at 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). Add the oil phase to the water phase, preliminarily emulsify, add the A phase, uniformly emulsify with a homomixer, and cool to 30 ° C. while stirring well after emulsification.
実施例5 乳液
(処方)
マイクロクリスタリンワックス 1.0 質量%
密ロウ 2.0
ラノリン 20.0
流動パラフィン 10.0
スクワラン 5.0
ソルビタンセスキオレイン酸エステル 4.0
ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 1.0
プロピレングリコール 7.0
Leontopodium jacotianum 水抽出物 10.0
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールを加え、加熱して70℃に保つ(水相)。他の成分を混合し、加熱融解して70℃に保つ(油相)。油相をかきまぜながらこれに水相を徐々に加え、ホモミキサーで均一に乳化する。乳化後よくかきまぜながら30℃まで冷却する。
Example 5 Latex (Prescription)
Microcrystalline wax 1.0% by mass
Beeswax 2.0
Lanolin 20.0
Liquid paraffin 10.0
Squalane 5.0
Sorbitan sesquioleate ester 4.0
Polyoxyethylene (20 mol) sorbitan monooleate 1.0
Propylene glycol 7.0
Leontopodium jacotianum water extract 10.0
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Propylene glycol is added to ion-exchanged water and heated to 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto and uniformly emulsified with a homomixer. Cool to 30 ° C. while stirring well after emulsification.
実施例6 ゼリー
(処方)
95%エチルアルコール 10.0 質量%
ジプロピレングリコール 15.0
ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0
カルボキシビニルポリマー 1.0
苛性ソーダ 0.15
L−アルギニン 0.1
Swertia alata 50%エタノール水溶液抽出物 7.0
2-ヒドロキシ-4-メトキシベンゾフェノンスルホン酸ナトリウム 0.05
エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05
メチルパラベン 0.2
香料 適量
イオン交換水 残余
(製法)
イオン交換水にカルボキシビニルポリマーを均一に溶解し、一方、95%エタノールにSwertia alata 50%エタノール水溶液抽出物、ポリオキシエチレン(50モル)オレイルアルコールエーテルを溶解し、水相に添加する。次いで、その他の成分を加えたのち苛性ソーダ、L−アルギニンで中和させ増粘する。
Example 6 Jelly (Prescription)
95% ethyl alcohol 10.0% by mass
Dipropylene glycol 15.0
Polyoxyethylene (50 mol) oleyl alcohol ether 2.0
Carboxyvinyl polymer 1.0
Caustic soda 0.15
L-Arginine 0.1
Swertia alata 50% aqueous ethanol extract 7.0
Sodium 2-hydroxy-4-methoxybenzophenone sulfonate 0.05
Ethylenediaminetetraacetate, 3 sodium, 2 water 0.05
Methylparaben 0.2
Perfume Appropriate amount Ion exchange water Residue
Dissolve the carboxyvinyl polymer uniformly in ion-exchanged water, while dissolving the Swertia alata 50% aqueous ethanol extract, polyoxyethylene (50 mol) oleyl alcohol ether in 95% ethanol and add to the aqueous phase. Next, after adding other components, the mixture is neutralized and thickened with caustic soda and L-arginine.
実施例7 美容液
(処方)
(A相)
エチルアルコール(95%) 10.0 質量%
ポリオキシエチレン(20モル)オクチルドデカノール 1.0
パントテニールエチルエーテル 0.1
Artemisia roxburghiana エタノール抽出物 1.5
メチルパラベン 0.15
(B相)
水酸化カリウム 0.1
(C相)
グリセリン 5.0
ジプロピレングリコール 10.0
亜硫酸水素ナトリウム 0.03
カルボキシビニルポリマー 0.2
精製水 残余
(製法)
A相、C相をそれぞれ均一に溶解し、C相にA相を加えて可溶化する。次いでB相を加えたのち充填を行う。
Example 7 Cosmetic liquid (prescription)
(Phase A)
Ethyl alcohol (95%) 10.0% by mass
Polyoxyethylene (20 mol) octyldodecanol 1.0
Pantotenyl ethyl ether 0.1
Artemisia roxburghiana ethanol extract 1.5
Methylparaben 0.15
(Phase B)
Potassium hydroxide 0.1
(Phase C)
Glycerin 5.0
Dipropylene glycol 10.0
Sodium bisulfite 0.03
Carboxyvinyl polymer 0.2
Purified water residue (production method)
A phase and C phase are uniformly dissolved, and A phase is added to C phase to solubilize. Next, filling is performed after adding phase B.
実施例8 パック
(処方)
(A相)
ジプロピレングリコール 5.0 質量%
ポリオキシエチレン(60モル)硬化ヒマシ油 5.0
(B相)
Callistemon lanceolatus エタノール抽出物 0.01
オリーブ油 5.0
酢酸トコフェロール 0.2
エチルパラベン 0.2
香料 0.2
(C相)
亜硫酸水素ナトリウム 0.03
ポリビニルアルコール 13.0
(ケン化度90、重合度2,000)
エタノール 7.0
精製水 残余
(製法)
A相、B相、C相をそれぞれ均一に溶解し、A相にB相を加えて可溶化する。次いでこれをC相に加えたのち充填を行う。
Example 8 Pack (Prescription)
(Phase A)
Dipropylene glycol 5.0% by mass
Polyoxyethylene (60 mol) hydrogenated castor oil 5.0
(Phase B)
Callistemon lanceolatus ethanol extract 0.01
Olive oil 5.0
Tocopherol acetate 0.2
Ethylparaben 0.2
Fragrance 0.2
(Phase C)
Sodium bisulfite 0.03
Polyvinyl alcohol 13.0
(Saponification degree 90, polymerization degree 2,000)
Ethanol 7.0
Purified water residue (production method)
A phase, B phase, and C phase are uniformly dissolved, and B phase is added to A phase to solubilize. Next, this is added to phase C and then filled.
実施例9 固形ファンデーション
(処方)
タルク 43.1 質量%
カオリン 15.0
セリサイト 10.0
亜鉛華 7.0
二酸化チタン 3.8
黄色酸化鉄 2.9
黒色酸化鉄 0.2
スクワラン 8.0
イソステアリン酸 4.0
モノオレイン酸POEソルビタン 3.0
オクタン酸イソセチル 2.0
Physalis divaricata エタノール抽出物 1.0
防腐剤 適量
香料 適量
(製法)
タルク〜黒色酸化鉄の粉末成分をブレンダーで十分混合し、これにスクワラン〜オクタン酸イソセチルの油性成分、Physalis divaricata エタノール抽出物、防腐剤、香料を加え良く混練した後、容器に充填、成型する。
Example 9 Solid Foundation (Prescription)
Talc 43.1% by mass
Kaolin 15.0
Sericite 10.0
Zinc flower 7.0
Titanium dioxide 3.8
Yellow iron oxide 2.9
Black iron oxide 0.2
Squalane 8.0
Isostearic acid 4.0
Monooleic acid POE sorbitan 3.0
Isocetyl octoate 2.0
Physalis divaricata ethanol extract 1.0
Preservative appropriate amount perfume appropriate amount (production method)
A powder component of talc to black iron oxide is sufficiently mixed with a blender, and an oily component of squalane to isocetyl octanoate, a Physalis divaricata ethanol extract, a preservative, and a fragrance are added and kneaded well, and then filled into a container and molded.
実施例10 乳化型ファンデーション(クリームタイプ)
(処方)
(粉体部)
二酸化チタン 10.3 質量%
セリサイト 5.4
カオリン 3.0
黄色酸化鉄 0.8
ベンガラ 0.3
黒色酸化鉄 0.2
(油相)
デカメチルシクロペンタシロキサン 11.5
流動パラフィン 4.5
ポリオキシエチレン変性ジメチルポリシロキサン 4.0
(水相)
精製水 50.0
1,3−ブチレングルコール 4.5
Senecio chrysanthemoides エタノール抽出物 1.5
ソルビタンセスキオレイン酸エステル 3.0
防腐剤 適量
香料 適量
(製法)
水相を加熱攪拌後、十分に混合粉砕した粉体部を添加してホモミキサー処理する。更に加熱混合した油相を加えてホモミキサー処理した後、攪拌しながら香料を添加して室温まで冷却する。
Example 10 Emulsification Foundation (Cream Type)
(Prescription)
(Powder part)
Titanium dioxide 10.3% by mass
Sericite 5.4
Kaolin 3.0
Yellow iron oxide 0.8
Bengala 0.3
Black iron oxide 0.2
(Oil phase)
Decamethylcyclopentasiloxane 11.5
Liquid paraffin 4.5
Polyoxyethylene-modified dimethylpolysiloxane 4.0
(Water phase)
Purified water 50.0
1,3-butylene glycol 4.5
Senecio chrysanthemoides ethanol extract 1.5
Sorbitan sesquioleate 3.0
Preservative appropriate amount perfume appropriate amount (production method)
After the aqueous phase is heated and stirred, the powder part sufficiently mixed and pulverized is added and homomixed. Furthermore, after adding the heat-mixed oil phase and carrying out a homomixer process, a fragrance | flavor is added, stirring, and it cools to room temperature.
実施例11 クリーム
(処方)
ステアリン酸 5.0 質量%
ステアリルアルコール 4.0
イソプロピルミリステート 18.0
グリセリンモノステアリン酸エステル 3.0
プロピレングリコール 10.0
Rabdosia coetsa エタノール抽出物 0.01
苛性カリ 0.2
亜硫酸水素ナトリウム 0.01
防腐剤 適量
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールと Rabdosia coetsa エタノール抽出物と苛性カリを加え溶解し、加熱して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を徐々に加え、全部加え終わってからしばらくその温度に保ち反応を起こさせる。その後、ホモミキサーで均一に乳化し、よくかきまぜながら30℃まで冷却する。
Example 11 Cream (Prescription)
Stearic acid 5.0% by mass
Stearyl alcohol 4.0
Isopropyl myristate 18.0
Glycerol monostearate 3.0
Propylene glycol 10.0
Rabdosia coetsa ethanol extract 0.01
Caustic potash 0.2
Sodium bisulfite 0.01
Preservative Appropriate amount Perfume Appropriate amount Ion-exchange water Residue
Propylene glycol, Rabdosia coetsa ethanol extract and caustic potash are added to ion-exchanged water, dissolved, heated and maintained at 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase, and after the addition is complete, the temperature is maintained for a while to cause the reaction. Thereafter, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well.
実施例12 クリーム
(処方)
ステアリン酸 2.0 質量%
ステアリルアルコール 7.0
水添ラノリン 2.0
スクワラン 5.0
2−オクチルドデシルアルコール 6.0
ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0
グリセリンモノステアリン酸エステル 2.0
プロピレングリコール 5.0
Cyperus sp. ヘキサン抽出物 0.05
亜硫酸水素ナトリウム 0.03
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールを加え、加熱して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却する。
Example 12 Cream (Prescription)
Stearic acid 2.0% by mass
Stearyl alcohol 7.0
Hydrogenated Lanolin 2.0
Squalane 5.0
2-Octyldodecyl alcohol 6.0
Polyoxyethylene (25 mol) cetyl alcohol ether 3.0
Glycerin monostearate ester 2.0
Propylene glycol 5.0
Cyperus sp. Hexane extract 0.05
Sodium bisulfite 0.03
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Propylene glycol is added to ion-exchanged water and heated to 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). Preliminarily emulsify by adding an oil phase to the aqueous phase, uniformly emulsify with a homomixer, and then cool to 30 ° C. while stirring well.
実施例13 クリーム
(処方)
固形パラフィン 5.0 質量%
ミツロウ 10.0
ワセリン 15.0
流動パラフィン 41.0
グリセリンモノステアリン酸エステル 2.0
ポリオキシエチレン(20モル)ソルビタンモノラウリン酸エステル 2.0
石けん粉末 0.1
硼砂 0.2
Leontopodium jacotianum アセトン抽出物 0.05
亜硫酸水素ナトリウム 0.03
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水に石けん粉末と硼砂を加え、加熱溶解して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相をかきまぜながら徐々に加え反応を行う。反応終了後、ホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却する。
Example 13 Cream (Prescription)
Solid paraffin 5.0% by mass
Beeswax 10.0
Vaseline 15.0
Liquid paraffin 41.0
Glycerin monostearate ester 2.0
Polyoxyethylene (20 mol) sorbitan monolaurate 2.0
Soap powder 0.1
Borax 0.2
Leontopodium jacotianum acetone extract 0.05
Sodium bisulfite 0.03
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Add soap powder and borax to ion-exchanged water, dissolve by heating and maintain at 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). The reaction is gradually added while stirring the oil phase in the aqueous phase. After completion of the reaction, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well after emulsification.
実施例14 乳液
(処方)
ステアリン酸 2.5 質量%
セチルアルコール 1.5
ワセリン 5.0
流動パラフィン 10.0
ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0
ポリエチレングリコール1500 3.0
トリエタノールアミン 1.0
カルボキシビニルポリマー 0.05
Swertia alata エチルエステル抽出物 0.01
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
少量のイオン交換水にカルボキシビニルポリマーを溶解する(A相)。残りのイオン交換水にポリエチレングリコール1500とトリエタノールアミンを加え、加熱溶解して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保つ(油相)。水相に油相を加え予備乳化を行い、A相を加えホモミキサーで均一乳化し、乳化後よくかきまぜながら30℃まで冷却する。
Example 14 Emulsion (Prescription)
Stearic acid 2.5% by mass
Cetyl alcohol 1.5
Vaseline 5.0
Liquid paraffin 10.0
Polyoxyethylene (10 mol) monooleate 2.0
Polyethylene glycol 1500 3.0
Triethanolamine 1.0
Carboxyvinyl polymer 0.05
Swertia alata ethyl ester extract 0.01
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Dissolve the carboxyvinyl polymer in a small amount of ion-exchanged water (A phase). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating and maintained at 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted, and kept at 70 ° C. (oil phase). Add the oil phase to the water phase, preliminarily emulsify, add the A phase, uniformly emulsify with a homomixer, and cool to 30 ° C. while stirring well after emulsification.
実施例15 乳液
(処方)
マイクロクリスタリンワックス 1.0 質量%
密ロウ 2.0
ラノリン 20.0
流動パラフィン 10.0
スクワラン 5.0
ソルビタンセスキオレイン酸エステル 4.0
ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 1.0
プロピレングリコール 7.0
Artemisia roxburghiana 抽出物 10.0
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
香料 適量
イオン交換水 残余
(製法)
イオン交換水にプロピレングリコールを加え、加熱して70℃に保つ(水相)。他の成分を混合し、加熱融解して70℃に保つ(油相)。油相をかきまぜながらこれに水相を徐々に加え、ホモミキサーで均一に乳化する。乳化後よくかきまぜながら30℃まで冷却する。
Example 15 Emulsion (Prescription)
Microcrystalline wax 1.0% by mass
Beeswax 2.0
Lanolin 20.0
Liquid paraffin 10.0
Squalane 5.0
Sorbitan sesquioleate ester 4.0
Polyoxyethylene (20 mol) sorbitan monooleate 1.0
Propylene glycol 7.0
Artemisia roxburghiana extract 10.0
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount Ion exchange water Residue
Propylene glycol is added to ion-exchanged water and heated to 70 ° C. (aqueous phase). The other ingredients are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto and uniformly emulsified with a homomixer. Cool to 30 ° C. while stirring well after emulsification.
実施例16 ゼリー
(処方)
95%エチルアルコール 10.0 質量%
ジプロピレングリコール 15.0
ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0
カルボキシビニルポリマー 1.0
苛性ソーダ 0.15
L−アルギニン 0.1
Callistemon lanceolatus 50%エタノール水溶液抽出物 7.0
2-ヒドロキシ-4-メトキシベンゾフェノンスルホン酸ナトリウム 0.05
エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05
メチルパラベン 0.2
香料 適量
イオン交換水 残余
(製法)
イオン交換水にカーボポール940を均一に溶解し、一方、95%エタノールに Callistemon lanceolatus 50%エタノール水溶液抽出物、ポリオキシエチレン(50モル)オレイルアルコールエーテルを溶解し、水相に添加する。次いで、その他の成分を加えたのち苛性ソーダ、L−アルギニンで中和させ増粘する。
Example 16 Jelly (Prescription)
95% ethyl alcohol 10.0% by mass
Dipropylene glycol 15.0
Polyoxyethylene (50 mol) oleyl alcohol ether 2.0
Carboxyvinyl polymer 1.0
Caustic soda 0.15
L-Arginine 0.1
Callistemon lanceolatus 50% aqueous ethanol extract 7.0
Sodium 2-hydroxy-4-methoxybenzophenone sulfonate 0.05
Ethylenediaminetetraacetate, 3 sodium, 2 water 0.05
Methylparaben 0.2
Perfume Appropriate amount Ion exchange water Residue
Carbopol 940 is uniformly dissolved in ion-exchanged water, while Callistemon lanceolatus 50% aqueous ethanol extract, polyoxyethylene (50 mol) oleyl alcohol ether is dissolved in 95% ethanol and added to the aqueous phase. Next, after adding other components, the mixture is neutralized and thickened with caustic soda and L-arginine.
Claims (3)
A method for producing a whitening skin external preparation, which comprises adding the whitening agent according to claim 1 to an aqueous phase or an oil phase to produce a whitening skin external preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006339530A JP2008150314A (en) | 2006-12-18 | 2006-12-18 | Bleaching agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006339530A JP2008150314A (en) | 2006-12-18 | 2006-12-18 | Bleaching agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008150314A true JP2008150314A (en) | 2008-07-03 |
Family
ID=39652889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006339530A Withdrawn JP2008150314A (en) | 2006-12-18 | 2006-12-18 | Bleaching agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008150314A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010195732A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor, beautifying agent and skin care preparation for external use |
| CN102389110A (en) * | 2011-11-02 | 2012-03-28 | 刘鹏 | Health product for treating chloasma |
| KR101147405B1 (en) * | 2009-09-03 | 2012-05-22 | 제주대학교 산학협력단 | Cosmetic composition containing extract of callistemon lanceolatus used for antiwrinkle |
| KR101195576B1 (en) | 2010-01-21 | 2012-10-29 | (주)더페이스샵 | Cosmetic Composition Cyperus Papyrus Extracts for Skin whitenig |
| US9227090B2 (en) | 2008-06-18 | 2016-01-05 | Conopco, Inc. | Method for lightening skin |
| US9445987B2 (en) | 2009-10-05 | 2016-09-20 | Kao Corporation | Ceramide production enhancer and moisturizer |
| JP2017502087A (en) * | 2014-01-10 | 2017-01-19 | コスモ インターナショナル イングレディエンツ | A plant extract containing, as an active ingredient, a sucrose ester used in a cosmetic composition, dermatological composition, or nutritional cosmetic composition |
| KR20220078062A (en) * | 2020-12-03 | 2022-06-10 | 대한민국(환경부 국립생물자원관장) | Cosmetic composition containing Cyperus spp. extract for antiinflammation or skin whitening |
-
2006
- 2006-12-18 JP JP2006339530A patent/JP2008150314A/en not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227090B2 (en) | 2008-06-18 | 2016-01-05 | Conopco, Inc. | Method for lightening skin |
| JP2010195732A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor, beautifying agent and skin care preparation for external use |
| KR101147405B1 (en) * | 2009-09-03 | 2012-05-22 | 제주대학교 산학협력단 | Cosmetic composition containing extract of callistemon lanceolatus used for antiwrinkle |
| US9445987B2 (en) | 2009-10-05 | 2016-09-20 | Kao Corporation | Ceramide production enhancer and moisturizer |
| US9682029B2 (en) | 2009-10-05 | 2017-06-20 | Kao Corporation | Ceramide production enhancer and moisturizer |
| KR101195576B1 (en) | 2010-01-21 | 2012-10-29 | (주)더페이스샵 | Cosmetic Composition Cyperus Papyrus Extracts for Skin whitenig |
| CN102389110A (en) * | 2011-11-02 | 2012-03-28 | 刘鹏 | Health product for treating chloasma |
| JP2017502087A (en) * | 2014-01-10 | 2017-01-19 | コスモ インターナショナル イングレディエンツ | A plant extract containing, as an active ingredient, a sucrose ester used in a cosmetic composition, dermatological composition, or nutritional cosmetic composition |
| KR20220078062A (en) * | 2020-12-03 | 2022-06-10 | 대한민국(환경부 국립생물자원관장) | Cosmetic composition containing Cyperus spp. extract for antiinflammation or skin whitening |
| KR102471026B1 (en) * | 2020-12-03 | 2022-11-29 | 대한민국 | Cosmetic composition containing Cyperus spp. extract for antiinflammation or skin whitening |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518101A (en) | Composition containing an extract of fly stalk for cosmetic treatment | |
| JP4530832B2 (en) | Skin external preparation for whitening, whitening agent, whitening method, and method for producing skin external preparation for whitening | |
| JP2008156325A (en) | Skin preparations and whitening agents | |
| JP2008150314A (en) | Bleaching agent | |
| JP2003176218A (en) | Skin care preparation | |
| JPH0812560A (en) | Skin external preparation | |
| US20100008879A1 (en) | Whitening agent | |
| JPH0812561A (en) | Beautifying and whitening skin preparation for external use | |
| JPH0987164A (en) | Skin preparation for external use | |
| JP2006257056A (en) | Estrogen-like agent and skin external preparation composition | |
| JP2010222273A (en) | Hair nourishing composition | |
| JP2008247841A (en) | Skin-lightening agent and melanin generation inhibitor | |
| JP2006257058A (en) | Lipase inhibitor, and hair preparation and skin external preparation containing the same. | |
| JP2007106675A (en) | Skin whitening agent | |
| JP3527406B2 (en) | Skin whitening external preparation | |
| JP3754025B2 (en) | Cell activator, antioxidant, and skin external preparation | |
| JP2006265141A (en) | Skin-whitening agent | |
| JPH0987135A (en) | Dermal preparation for external use | |
| JP4764079B2 (en) | Whitening agent | |
| JPH10265363A (en) | Tyrosinase inhibitor | |
| KR101028701B1 (en) | Cosmetic composition for improving skin whitening including camellia surgery powder or camellia surgery extract | |
| JP2007126367A (en) | Bleaching ingredient, bleaching method and method for producing bleaching skin care preparation | |
| KR100518779B1 (en) | Dermatologic preparations for beautifying | |
| JP2009191043A (en) | Elastase inhibitor | |
| KR101457784B1 (en) | A Skin External Composition Containing Callus Extract Derived from Bupleurm falcatum L. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20100302 |